{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:14:06Z","timestamp":1754144046917,"version":"3.41.2"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,14]]},"DOI":"10.7759\/cureus.87950","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T05:19:54Z","timestamp":1752556794000},"source":"Crossref","is-referenced-by-count":0,"title":["Neurologic Adverse Events Associated With T-cell Engager Therapy in Multiple Myeloma: A Pharmacovigilance Study"],"prefix":"10.7759","author":[{"given":"Muhammad Atif","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiza Humayun","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohaib","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Mahmoudjafari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Multiple myeloma","author":"Albagoush SA","year":"2024","unstructured":"Albagoush SA, Shumway C, Azevedo AM. Multiple myeloma. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref2","unstructured":"Cancer stat facts. myeloma. (2025). Accessed: February 15, 2025: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"ref3","unstructured":"FDA approves first cell-based gene therapy for adult patients with multiple myeloma. (2021). Accessed. May 15, 2025: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cell-based-gene-therapy-adult-patients-multipl...."},{"key":"ref4","unstructured":"FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. (2022). Accessed. May 15, 2025: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-ref...."},{"key":"ref5","unstructured":"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. (2022). Accessed. May 15, 2025: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-m...."},{"key":"ref6","unstructured":"FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma. (2023). Accessed. May 15, 2025: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-talquetamab-tgvs-relap...."},{"key":"ref7","unstructured":"FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma. (2023). Accessed. May 15, 2025: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-elranatamab-bcmm-multi...."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/antib12020038","article-title":"The role of bispecific antibodies in relapsed refractory multiple myeloma: a systematic review","volume":"12","author":"Khanam R","year":"2023","unstructured":"Khanam R, Ashruf OS, Waqar SH, et al.. The role of bispecific antibodies in relapsed refractory multiple myeloma: a systematic review. Antibodies (Basel). 2023, 12:10.3390\/antib12020038","journal-title":"Antibodies (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175539","article-title":"Management of adverse reactions for BCMA-directed therapy in relapsed multiple myeloma: a focused review","volume":"12","author":"Khanam R","year":"2023","unstructured":"Khanam R, Faiman B, Batool S, et al.. Management of adverse reactions for BCMA-directed therapy in relapsed multiple myeloma: a focused review. J Clin Med. 2023, 12:10.3390\/jcm12175539","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen AD","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, et al.. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022, 12:10.1038\/s41408-022-00629-1","journal-title":"Blood Cancer J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin AM","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al.. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023, 29:2259-67. 10.1038\/s41591-023-02528-9","journal-title":"Nat Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau P","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NW, et al.. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022, 387:495-505. 10.1056\/NEJMoa2203478","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari A","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, et al.. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022, 387:2232-44. 10.1056\/NEJMoa2204591","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao X","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, Li Y. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021, 40:10.1186\/s13046-021-02148-6","journal-title":"J Exp Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186663","article-title":"Taste abnormalities emerging during anti-myeloma therapies including GPRC5D x CD3 bispecific antibody talquetamab","volume":"142","author":"Fleischer A","year":"2023","unstructured":"Fleischer A, Roll M, Panther F, et al.. Taste abnormalities emerging during anti-myeloma therapies including GPRC5D x CD3 bispecific antibody talquetamab. Blood. 2023, 142:10.1182\/blood-2023-186663","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/380586-neurologic-adverse-events-associated-with-t-cell-engager-therapy-in-multiple-myeloma-a-pharmacovigilance-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T05:19:56Z","timestamp":1752556796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/380586-neurologic-adverse-events-associated-with-t-cell-engager-therapy-in-multiple-myeloma-a-pharmacovigilance-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.87950","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,14]]}}}